Bug drugs
A study into the way that the tropical parasite Leishmania uses the nutrients they need to grow has provided researchers with drug targets that could be used to combat them.
A study into the way that the tropical parasite Leishmania uses the nutrients they need to grow has provided researchers with drug targets that could be used to combat them.
Leishmania are tropical parasites that proliferate in sandflies and are transferred to mammals when they are bitten by the fly. They infect 12 million people worldwide, causing a range of reactions, from skin conditions to organ infection, and are responsible for 500 000 deaths annually.
A study, published in the Journal of Biological Chemistry,1 has developed an analytical method that has revealed the metabolic pathways essential for the parasite’s survival, down to the particular atoms it uses as a food source. To study the metabolism 13C-labelled carbon sources were introduced into the sugar glucose that the parasites feed on. Gas chromatography–mass spectrometry and nuclear magnetic resonance were then used to follow how the atoms were incorporated by the parasite, revealing the metabolic pathways essential to the parasite’s survival, which would, therefore, be good drug targets to block to kill it.
According to the authors, current anti-parasitic drugs have enormous side effects, as they don’t target specific pathogen metabolic pathways. With a greater understanding of the parasite, specific drugs can be developed with minimal side effects.
1. E.C. Saunders et al., J. Biol. Chem.,286, 27706–27717 (2011).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
